<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:32:19Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2444026" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2444026</identifier><datestamp>2008-07-16</datestamp><setSpec>plosone</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2444026</article-id>
      <article-id pub-id-type="pmcid">PMC2444026</article-id>
      <article-id pub-id-type="pmc-uid">2444026</article-id>
      <article-id pub-id-type="pmid">18628956</article-id>
      <article-id pub-id-type="pmid">18628956</article-id>
      <article-id pub-id-type="publisher-id">08-PONE-RA-04339R1</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0002721</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Oncology</subject>
          <subject>Biochemistry/Transcription and Translation</subject>
          <subject>Genetics and Genomics/Gene Expression</subject>
          <subject>Molecular Biology/Transcription Initiation and Activation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>TAF6Î´ Controls Apoptosis and Gene Expression in the Absence of p53</article-title>
        <alt-title alt-title-type="running-head">TAF6Î´ Controls Death Sans p53</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wilhelm</surname>
            <given-names>Emmanuelle</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pellay</surname>
            <given-names>FranÃ§ois-Xavier</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Benecke</surname>
            <given-names>Arndt</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bell</surname>
            <given-names>Brendan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
<label>1</label>
<addr-line>RNA Group, DÃ©partement de microbiologie et d'infectiologie, FacultÃ© de mÃ©decine et sciences de la santÃ©, UniversitÃ© de Sherbrooke, Sherbrooke, QuÃ©bec, Canada</addr-line>
</aff>
      <aff id="aff2">
<label>2</label>
<addr-line>Institut des Hautes Ãtudes Scientifiques and Institut de Recherche Interdisciplinaire â CNRS USR3078 - UniversitÃ© de Lille, Bures sur Yvette, France</addr-line>
</aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Imhof</surname>
            <given-names>Axel</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">University of Munich and Center of Integrated Protein Science, Germany</aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email>Brendan.Bell@USherbrooke.ca</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: AB BB. Performed the experiments: EW. Analyzed the data: FP AB BB. Wrote the paper: EW AB BB.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>7</month>
        <year>2008</year>
      </pub-date>
      <volume>3</volume>
      <issue>7</issue>
      <elocation-id>e2721</elocation-id>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>4</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>6</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Wilhelm et al.</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Life and death decisions of metazoan cells hinge on the balance between the expression of pro- versus anti-apoptotic gene products. The general RNA polymerase II transcription factor, TFIID, plays a central role in the regulation of gene expression through its core promoter recognition and co-activator functions. The core TFIID subunit TAF6 acts <italic>in vitro</italic> as an essential co-activator of transcription for the p53 tumor suppressor protein. We previously identified a splice variant of TAF6, termed TAF6Î´ that can be induced during apoptosis.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>To elucidate the impact of TAF6Î´ on cell death and gene expression, we have employed modified antisense oligonucleotides to enforce expression of endogenous TAF6Î´. The induction of endogenous TAF6Î´ triggered apoptosis in tumor cell lines, including cells devoid of p53. Microarray experiments revealed that TAF6Î´ activates gene expression independently of cellular p53 status.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Our data define TAF6Î´ as a pivotal node in a signaling pathway that controls gene expression programs and apoptosis in the absence of p53.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="13"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Tightly controlled programmed cell death is essential for the development and tissue homeostasis of all animals. Metazoan cells possess an evolutionary conserved network of proteins (e.g. caspases, Bcl-2 family members and death receptors) that execute appropriate life or death decisions in response to extrinsic and intrinsic cellular cues <xref rid="pone.0002721-Hengartner1" ref-type="bibr">[1]</xref>. Deregulated apoptosis underlies numerous human disease states including neurodegenerative disorders and cancer <xref rid="pone.0002721-Thompson1" ref-type="bibr">[2]</xref>. The identification and molecular characterization of the critical control points in apoptotic pathways is therefore essential to reveal novel therapeutic avenues to treat a broad array of human pathologies.</p>
      <p>Gene expression plays a key role in the response of cells to death-inducing stimuli. A growing body of evidence indicates that the levels of numerous death-related genes can be induced during apoptosis <xref rid="pone.0002721-Fesus1" ref-type="bibr">[3]</xref>. The integration of cellular signals from diverse apoptotic pathways requires the finely balanced expression of pro- versus anti-apoptotic proteins. Gene expression patterns of pro- and anti-apoptotic genes, established by the levels of transcription <xref rid="pone.0002721-Kumar1" ref-type="bibr">[4]</xref> as well as alternative splicing <xref rid="pone.0002721-Schwerk1" ref-type="bibr">[5]</xref>, can dictate the life-or-death decisions of cells. The most intensely studied protein known to control apoptosis by altering gene expression is the p53 tumor suppressor. Current paradigms link the p53 tumor suppression function to its capacity to induce apoptosis in response to genotoxic stress <xref rid="pone.0002721-Vousden1" ref-type="bibr">[6]</xref>. The pro-apoptotic activity of p53 depends largely on its function as a transcriptional activator that binds directly to the promoters of pro-apoptotic genes including <italic>FDXR</italic>
<xref rid="pone.0002721-Liu1" ref-type="bibr">[7]</xref>, <xref rid="pone.0002721-Hwang1" ref-type="bibr">[8]</xref>, <italic>PUMA</italic>
<xref rid="pone.0002721-Yu1" ref-type="bibr">[9]</xref>, <italic>Noxa</italic>
<xref rid="pone.0002721-Oda1" ref-type="bibr">[10]</xref>, Bax <xref rid="pone.0002721-Miyashita1" ref-type="bibr">[11]</xref> and <italic>p53AIP1</italic>
<xref rid="pone.0002721-Oda2" ref-type="bibr">[12]</xref>.</p>
      <p>TFIID is a multi-protein complex that plays a pivotal role in the transcription of protein-coding genes in eukaryotes. TFIID is composed of the TATA-binding protein (TBP) and up to 14 evolutionarily conserved TBP-associated factors (TAFs) <xref rid="pone.0002721-Bell1" ref-type="bibr">[13]</xref>, <xref rid="pone.0002721-Green1" ref-type="bibr">[14]</xref>. TFIID can play a rate-limiting role in the regulation of transcription through the recognition of the core promoter elements such as the TATA-box, the initiator, and downstream promoter element (DPE) <xref rid="pone.0002721-Muller1" ref-type="bibr">[15]</xref>. The TFIID complex also engages in direct contacts with DNA-binding transcriptional factors to co-activate gene expression <xref rid="pone.0002721-Albright1" ref-type="bibr">[16]</xref>. The architecture and integrity of TFIID complexes depends on a network of TAF-TAF interactions that are predominantly mediated by dimerization of TAFs via their interlocking histone fold motifs <xref rid="pone.0002721-Gangloff1" ref-type="bibr">[17]</xref>. Histone-fold pairs within TFIID include TAF6-TAF9 <xref rid="pone.0002721-Xie1" ref-type="bibr">[18]</xref>, TAF4-TAF12 <xref rid="pone.0002721-Werten1" ref-type="bibr">[19]</xref>, TAF11-13 <xref rid="pone.0002721-Birck1" ref-type="bibr">[20]</xref>, TAF8-TAF10 <xref rid="pone.0002721-Gangloff2" ref-type="bibr">[21]</xref> and TAF3-TAF10 <xref rid="pone.0002721-Gangloff3" ref-type="bibr">[22]</xref>. TAF4 and TAF5 together with the histone fold containing TAF12, TAF9 and TAF6 are defined as core TAFs, since their depletion from <italic>Drosophila</italic> cells results in overall destabilization of TFIID complexes <xref rid="pone.0002721-Wright1" ref-type="bibr">[23]</xref>.</p>
      <p>The core TFIID subunit TAF6 (hTAF<sub>II</sub>70/80) has been shown to be broadly required for RNA polymerase II (Pol II) transcription in yeast when total poly(A)<sup>+</sup> mRNA levels were monitored <xref rid="pone.0002721-Michel1" ref-type="bibr">[24]</xref>. A more recent microarray analysis estimated that approximately 18% of the yeast Pol II transcriptome depends on TAF6 <xref rid="pone.0002721-Shen1" ref-type="bibr">[25]</xref>. TAF6 has been shown to be essential for viability in yeast <xref rid="pone.0002721-Michel1" ref-type="bibr">[24]</xref>, <xref rid="pone.0002721-Poon1" ref-type="bibr">[26]</xref>, plants <xref rid="pone.0002721-Lago1" ref-type="bibr">[27]</xref>, insects <xref rid="pone.0002721-Aoyagi1" ref-type="bibr">[28]</xref> and fish <xref rid="pone.0002721-Amsterdam1" ref-type="bibr">[29]</xref>. The requirement for TAF6 in all model organisms studied, together with the fact that human cells have a single <italic>TAF6</italic> gene <xref rid="pone.0002721-Purrello1" ref-type="bibr">[30]</xref>, <xref rid="pone.0002721-Weinzierl1" ref-type="bibr">[31]</xref>, strongly implies that TAF6 is essential for human cell viability.</p>
      <p>TAF6 and TAF6-TAF9 dimers can bind to the downstream promoter element (DPE) <xref rid="pone.0002721-Burke1" ref-type="bibr">[32]</xref>, <xref rid="pone.0002721-Shao1" ref-type="bibr">[33]</xref>. In addition to its core promoter recognition function, TAF6 can also interact with transcriptional activators. For example, <italic>in vitro</italic> experiments have shown that both TAF6 <xref rid="pone.0002721-Thut1" ref-type="bibr">[34]</xref>, and its dimerization partner TAF9 <xref rid="pone.0002721-Lu1" ref-type="bibr">[35]</xref>, interact directly with p53 and are required for the activation of transcription by p53. The available evidence implies that the TAF6-p53 interaction is required for the activation of at least some, and potentially all, p53 target genes <italic>in vivo</italic>
<xref rid="pone.0002721-Farmer1" ref-type="bibr">[36]</xref>, <xref rid="pone.0002721-Jimenez1" ref-type="bibr">[37]</xref>, <xref rid="pone.0002721-Johnson1" ref-type="bibr">[38]</xref>.</p>
      <p>We have identified and characterized a splice variant termed TAF6Î´ that lacks 10 amino acids in the centre of its histone fold domain <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. TAF6Î´ is unable to interact with TAF9, but retains interactions with other TFIID subunits. TAF6Î´ expression is induced in promyelocytic HL-60 cells undergoing retinoic-acid dependent apoptosis. TAF6Î´ overexpression induces apoptosis in HeLa cells, evoking the possibility that TFIID function could be coupled to certain apoptotic pathways via TAF6Î´. Importantly, however, it is not currently known if changes in the expression of endogenous TAF6Î´ can influence tumor cell death. Furthermore, despite the physical and functional interactions between the pivotal tumor suppressor p53 and TAF6 <xref rid="pone.0002721-Thut1" ref-type="bibr">[34]</xref>, nothing is currently known about whether p53 is required for TAF6Î´-mediated apoptosis. Here, we have used splice-site switching modified antisense RNA technology to demonstrate that endogenous TAF6Î´ controls apoptosis and that p53 is not required for TAF6Î´-dependent apoptosis or TAF6Î´-dependent gene expression.</p>
    </sec>
    <sec id="s2">
      <title>Materials and Methods</title>
      <sec id="s2a">
        <title>Cell culture</title>
        <p>HeLa cells were grown in DMEM containing 2.5% CS and 2.5% FCS. Saos-2 and H1299 cell lines were cultured in DMEM with 10% FCS. A549 cells were grown in Ham's F12 medium with 10% FCS. HCT-116 cells were grown in McCoy's media supplemented with 10% FCS. When indicated, cells were treated with the proteasome inhibitor MG-132 (Calbiochem) at 0.5 ÂµM and/or pan-caspase inhibitor Z-VAD-FMK (Biomol) at 100 ÂµM.</p>
      </sec>
      <sec id="s2b">
        <title>Transfections</title>
        <p>Oligonucleotides were transfected with lipofectamine 2000 (Invitrogen) as a delivery agent (1.6 Âµl/ml) according to the manufacturer's recommendations. 2â²-O-methyl-oligoribonucleoside phosphorothioate antisense 20-mers were from Sigma-Proligo. âTAF6 AS1â <named-content content-type="gene">5â²-CGAUCUCUUUGAUGCGGUAG-3â²</named-content> targets the central 20 nucleotides of the alternative exon 2 of TAF6, âTAF6 AS2â <named-content content-type="gene">5â²-GCCGGGUCACCUGUGCGAUC-3â²</named-content> the constitutive alpha 5â² splice site. âControl ASâ <named-content content-type="gene">5â²-AUGGCCUCGACGUGCGCGCU-3â²</named-content> is a scrambled oligo used as a negative control. âBcl-x ASâ <named-content content-type="gene">5â²-ACCCAGCCGCCGUUCUCC-3â²</named-content> targets the 5â²-splice site of Bcl-x<sub>L</sub>
<xref rid="pone.0002721-Mercatante1" ref-type="bibr">[40]</xref>. Plasmids were transfected using 1 Âµl DMRIE-C (Invitrogen) as a delivery agent in a 24 well plate according to the manufacturer's recommendations. All transfections were performed in OptiMEM medium (Invitrogen).</p>
      </sec>
      <sec id="s2c">
        <title>RT-PCR</title>
        <p>Total RNA was isolated from cells using Trizol (Invitrogen) according to the manufacturer's recommendations. 1 Âµg of total RNA was reverse transcribed using AMV-RT (Roche). 1/10 of the total cDNA was used per PCR reaction : 95Â°C, 3 min; 25 cycles of 94Â°C for 1 min, 58Â°C for 45 sec, 68Â°C for 50 sec; final extension at 68Â°C for 5 min with the following oligonucleotide pairs. For Taf6; forward <named-content content-type="gene">5â²-ATGGGCATCGCCCAGATTCAGG-3â²</named-content> and reverse <named-content content-type="gene">5â²-AAGGCGTAGTCAATGTCACTGG-3â²</named-content>. For Bcl-x; forward <named-content content-type="gene">5â²-TCATTTCCGACTGAAGAGTGA-3â²</named-content> and reverse <named-content content-type="gene">5â²-ATGGCAGCAGTAAAGCAAGCG-3â²</named-content>
</p>
      </sec>
      <sec id="s2d">
        <title>Apoptosis assays</title>
        <p>Detection of caspase cleaved cytokeratin-18 by flow cytometry was performed using Cytodeath reagent (Roche) according to the manufacturer's recommendations. Flow cytometric analysis of sub-G1 DNA content was performed as described <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>.</p>
      </sec>
      <sec id="s2e">
        <title>Plasmids</title>
        <p>To construct pASTAF6, the genomic region of <italic>TAF6</italic> containing exon2 to exon4 was amplified by PCR from HEK 293 genomic DNA with primers <named-content content-type="gene">5â²-GGAGAAGAGGGACTCCAGAATGGCTG-3â²</named-content> (forward) and <named-content content-type="gene">5â²-TCCCCCAACCTTTGAGGCAGACG-3â²</named-content> (reverse). The resulting product was digested with HindIII and SmaI and inserted into the same sites of the plasmid pXJ42hTAF<sub>II</sub>80Î± <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>.</p>
      </sec>
      <sec id="s2f">
        <title>Antibodies</title>
        <p>Monoclonal antibodies directed against TAF6Î´ (37TA-1 &amp; 37TA-2), TAF6Î± (25TA) <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>, TBP (3G3) <xref rid="pone.0002721-Brou1" ref-type="bibr">[41]</xref>, and TAF5 (2D2) <xref rid="pone.0002721-Dubrovskaya1" ref-type="bibr">[42]</xref> have been described. Monoclonal antibodies against TAF6 and PARP-1 were purchased from BD Transduction Laboratories and Biomol, respectively.</p>
      </sec>
      <sec id="s2g">
        <title>Immunocytochemistry</title>
        <p>Cells were fixed in 4% PFA, permeabilized with PBS-0.1% Triton X-100 (PBS-Tx) and incubated for 30 min in blocking buffer (PBS-Tx containing 1% bovine serum albumin (BSA) and 0.5% fish gelatine (Sigma-Aldrich)). Cells were then sequentially incubated one hour at room temperature, followed by washes, with each of the following antibodies diluted in blocking buffer; anti-TAF6 mAb (1/400), Oregon Green goat anti-mouse IgG secondary antibody (Molecular Probes), anti-TAF6Î´ mAb (37TA-1: 1/1000), Alexa Fluor 546 goat anti-mouse IgG<sub>1</sub> secondary antibody (Molecular Probes). Cells were then treated with Hoechst 33342 (2 Âµg/ml) and visualized by fluorescence microscopy.</p>
      </sec>
      <sec id="s2h">
        <title>Microarray Analysis of Gene Expression</title>
        <sec id="s2h1">
          <title>Transcriptome Acquisition</title>
          <p>Total RNA was analyzed using ABI Human Whole Genome Survey Arrays v1.0 arrays (Prod. No.: 4359030), containing 31,700 60-mer oligonucleotide probes representing a set of 27,868 individual annotated human genes. Chemiluminescence detection technology is used to detect as little as a femtomole of expressed mRNA. One single round of linear amplification was performed from total RNA according to the Applied Biosystems RT-IVT (Applied Biosystems, ProdNo: 4339628) protocol using 2 Âµg of total RNA. cDNA synthesis, <italic>in vitro</italic> transcription and labeling, fragmentation, hybridization, staining, and scanning were performed as directed by the supplier (Applied Biosystems, ProdNo: 4346875).</p>
        </sec>
        <sec id="s2h2">
          <title>Transcriptome Data Analysis</title>
          <p>Applied Biosystems Expression Array System Software v1.1.1. (ProdNo: 4364137) has been used to acquire the chemiluminescence and fluorescence images and primary data analysis. We renormalized the resulting data according to the logarithmic signal median once more after having removed control probes and those probes for which the Applied Biosystems Software has set flags equal to or greater than 2<sup>12</sup>, indicating compromised measurements (as recommended by Applied Biosystems). Log<sub>2</sub> subtractions were determined using averages over the weighted individual signal values. The weights are anti-proportional to the corresponding coefficient of variation. For these inter-assay comparisons the NeONORM method was used for normalization using sensitivity parameter <italic>k</italic>â=â0.20 <xref rid="pone.0002721-Noth1" ref-type="bibr">[43]</xref>. P-values were determined using a standard ANOVA method. Multiple probes for a single gene, cross-reactivity of a single probe to several genes, as well as the resolution of probe-ID annotations were done according to the standards defined previously <xref rid="pone.0002721-Noth2" ref-type="bibr">[44]</xref>. Gene lists corresponding to statistically significant changes in expression (P&lt;0.05) are available as supplementary data files: genes changing in response TAF6Î´ in HCT-116 p53 +/+ cells (Supplementary <xref ref-type="supplementary-material" rid="pone.0002721.s002">Data File S1</xref>), genes changing in response to TAF6Î´ in HCT-116 p53 â/â (Supplementary <xref ref-type="supplementary-material" rid="pone.0002721.s003">Data File S2</xref>), genes differentially expressed in the HCT-116 p53 +/+ cells versus HCT-116 p53 â/â cells both in cells treated with control oligonucleotide and TAF6Î´-inducing oligonucleotides (Supplementary <xref ref-type="supplementary-material" rid="pone.0002721.s004">Data File S3</xref>), and genes differentially regulated by TAF6Î´ in both HCT-116 p53 +/+ cells and HCT-116 p53 â/â cells (Supplementary <xref ref-type="supplementary-material" rid="pone.0002721.s005">Data File S4</xref>).</p>
          <p>The microarray data for the experiments described here were deposited in the Gene Expression Omnibus database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) under accession number: GSE10795.</p>
          <p>The supplementary data files can also be accessed from the Benecke group webpage: <ext-link ext-link-type="uri" xlink:href="http://seg.ihes.fr/">http://seg.ihes.fr/</ext-link>.</p>
        </sec>
      </sec>
      <sec id="s2i">
        <title>Real time PCR</title>
        <p>Real Time PCR was performed on cDNA prepared as for microarray experiments (above) using ABI TaqManÂ® assays. The genes and their respective assay numbers were ATF3 (Hs 00231069_m1), ACRC (Hs 00369516_m1), FNBP4 (Hs 00392543_m1) HES1 (Hs 00172878_m1), and HOM-TES-103 (Hs 00209961_m1). Real-time PCR was performed on 10 ng of cDNA with 1.25 Âµl of 20Ã TaqManÂ® probes and 12.5 Âµl 2Ã TaqManÂ® Universal Master Mix (ABI) in a final 25 Âµl reaction. Real-time PCR relative quantification assay was running for 2 min at 50Â°C, 10 min at 95Â°C, followed by 40 cycles of 15 sec at 95Â°C and 1 min at 60Â°C on an ABI 7500 system. Relative quantity of target genes was calculated using the comparative C<sub>T</sub> (ÎÎC<sub>T</sub>) method using FNBP4 as the internal control.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Selective induction of endogenous TAF6Î´ mRNA expression by splice-switching oligonucleotides</title>
        <p>To date four splice variants of TAF6 have been identified and termed Î±, Î², Î³, and Î´ <xref rid="pone.0002721-Weinzierl1" ref-type="bibr">[31]</xref>, <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>, <xref rid="pone.0002721-Wang1" ref-type="bibr">[45]</xref>. Here we focus on the TAF6Î´ splice variant due to its potentially important role in programmed cell death <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. The total number of distinct TAF6 mRNA species produced by alternative splicing has not yet been established. For clarity, we therefore refer here collectively to all TAF6 splice variants lacking the 30 nucleotide exon IIÎ± as TAF6Î´ and to TAF6Î± as all species of mRNA containing exon IIÎ± (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1</xref>). The <italic>TAF6</italic> genomic locus shows that the major TAF6Î± isoform is produced by the selection of an intron proximal 5â² splice site (SS) (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1A</xref>). In contrast, the TAF6Î´ isoform is produced by an alternative splicing event at the intron distal 5â² SS (labelled Î´ in <xref ref-type="fig" rid="pone-0002721-g001">Fig. 1A</xref>).</p>
        <fig id="pone-0002721-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0002721.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Specific control of endogenous TAF6 alternative splicing by modified antisense RNA oligonucleotides in living cells.</title>
            <p>(A) The region of the TAF6 pre-mRNA that includes two alternative 5â² splice sites (SSs) that produce either the constitutive Î± splice variant or the alternative Î´ splice variant is schematically depicted. Selection of an intron-proximal Î± 5â² splice site (SS) results in production of the Î± isoform of TAF6 (at right) whereas the selection of the proximal Î´ 5â² SS results in the production of the Î´ isoform (at left). The SSOs that base pair with the alternative exon forces splicing from the distal 5â² SS and induces expression of the endogenous TAF6Î´ isoform (at left). The protein produced by the major splice variant, TAF6Î±, can interact with the TFIID subunit, TAF9 via its histone fold domain. In contrast, TAF6Î´ lacks 10 amino acids of helix 2 of its histone fold motif and therefore cannot interact with TAF9. (B) Antisense RNA oligonucleotides induce endogenous TAF6Î´ mRNA expression. HeLa cells were transfected with 200 nM oligonucleotides directed against: the alternative exon II (exon IIÎ±) of the TAF6 gene (Taf6 AS1), the Bcl-x gene (Bcl-x AS), or a scrambled control oligonucleotide (Control AS). 24 hours post-transfection total RNA was isolated and subjected to RT-PCR with primers that amplify both the TAF6Î± and the alternative TAF6Î´ mRNAs. (C) Specificity of TAF6 splice site switching oligonucleotides. HeLa cells were transfected with antisense RNA oligonucleotides as in A. RT-PCR was perfomed with primers sets that amplify the both the Î± and Î´ TAF6 splice variants, or both the Bcl-xS and Bcl-xL splice variants. PCR products were separated by microfluidity and analyzed using a 2100 Agilent bioanalyzer. The ratio of TAF6Î´ mRNA over total TAF6 mRNA and the ratio of Bcl-Xs mRNA over total Bcl-X mRNA are expressed on the y-axis. The values from cells treated with scrambled control (grey bars), Taf6 AS1 (black bars), or Bcl-X AS (white bars) are shown. Error bars represent the standard deviation of three independent transfections.</p>
          </caption>
          <graphic xlink:href="pone.0002721.g001"/>
        </fig>
        <p>To dissect the biological role of endogenous TAF6Î´, we exploited <underline>s</underline>plice-<underline>s</underline>witching <underline>o</underline>ligonucleotides (SSOs) <xref rid="pone.0002721-Mercatante1" ref-type="bibr">[40]</xref>, <xref rid="pone.0002721-Taylor1" ref-type="bibr">[46]</xref> to experimentally manipulate endogenous TAF6 alternative splicing. The HeLa cell system represents a natural cellular context to study TAF6Î´ function because the TAF6Î´ variant was originally cloned from a HeLa cell cDNA library <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. We transfected HeLa cells with synthetic 2â²-<italic>O</italic>-methyl-modified oligoribonucleoside phosphorothioate that hybridizes to the central 20 nucleotides of alternative exon IIÎ± (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1A</xref>). The ratio of the alternative TAF6Î´ mRNA level with respect to TAF6Î± mRNA level was analyzed by RT-PCR of RNA samples from transfected HeLa cells. The transfection of the antisense oligonucleotide Taf6 AS1 resulted in a marked increase in the level of the TAF6Î´ mRNA and a concurrent decrease in the level of the major TAF6Î± mRNA (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1B</xref>, lane 3). In contrast, transfection of an oligonucleotide of scrambled sequence had no effect on the TAF6Î´/TAF6Î± mRNA ratio (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1B</xref>, lane 2). To further demonstrate the specificity of the SSOs, we transfected antisense RNA oligonucleotides shown to enforce the expression of the Bcl-xS splice variant <xref rid="pone.0002721-Mercatante1" ref-type="bibr">[40]</xref>. The TAF6Î´/TAF6Î±+Î´ mRNA ratio was increased â¼3-fold by treatment with the Taf6 AS1 oligonucleotide, but unchanged by the Bcl-x AS oligonucleotide (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref>). Conversely the ratio of Bcl-xS/Bcl-xL+xS mRNA was increased â¼10-fold by Bcl-x AS but unaffected by Taf6 AS1 (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref>). Control RT-PCR reactions showed that ratio of TAF6Î´ with respect to total TAF6 mRNA is increased by Taf6 SSO but none of the ratios of any other known TAF6 alternative splice variants was affected (data not shown). The SSOs used therefore impact specifically on TAF6Î´ alternative splicing without influencing overall expression patterns of TAF6 mRNA. These results demonstrate that TAF6-directed SSOs are an efficient and selective method to enforce the expression of the endogenous TAF6Î´ mRNA in HeLa cells.</p>
        <p>To further characterize the cellular response to TAF6 splice site switching antisense oligonucleotides we performed a time course analysis. The level of TAF6Î´ mRNA is detectably increased after 4 hours and increases until 24 hours (Supplementary <xref ref-type="supplementary-material" rid="pone.0002721.s001">Fig. S1A</xref>). These results are consistent with a previous study targeting the Bcl-x gene <xref rid="pone.0002721-Mercatante1" ref-type="bibr">[40]</xref>, and establish a kinetic framework to follow the early outcomes of TAF6Î´ mRNA expression in transfected cells. We next investigated the concentration dependence for the Taf6 response to treatment with the AS1 oligonucleotide. The induction of TAF6Î´ mRNA was observed with transfection of as little as 50 nM Taf6 AS1 and sharply increased until treatment with 200 nM Taf6 AS1, after which a plateau was reached (Supplementary <xref ref-type="supplementary-material" rid="pone.0002721.s001">Fig. S1B</xref>). Based on these results, we have employed 200 nM oligonucleotide concentrations herein, unless otherwise stated, for robust and specific induction of endogenous TAF6Î´ mRNA in living cells.</p>
      </sec>
      <sec id="s3b">
        <title>Splice-switching oligonucleotides increase endogenous TAF6Î´ protein levels</title>
        <p>We next investigated the influence of the splice site switching oligonucleotides on the levels of TAF6Î´ and TAF6Î± proteins. TAF6 was detected by immunocytochemistry using monoclonal antibodies that recognize an epitope present in all of the known isoforms of TAF6. HeLa cells treated with negative control oligonucleotides showed strong TAF6 staining throughout the entire nucleoplasm (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>). The nuclear total TAF6 immunofluorescent signal is diminished in cells treated with SSOs that increase TAF6Î´ mRNA production (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>), presumably due to decreased expression of TAF6Î± (see also below). TAF6Î´ was detected by immunofluorescence with monoclonal antibodies that specifically recognize the delta TAF6 isoform <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. HeLa cells transfected with negative control antisense oligonucleotides exhibited undetectable cellular staining with anti-TAF6Î´ monoclonal antibodies (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>). In contrast, transfection of HeLa cells with oligonucleotides that induce TAF6Î´ mRNA expression resulted in punctate nuclear staining (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>). We further quantified the influence of antisense treatment by scoring the number of cells displaying clear nuclear TAF6Î´ immunofluorescent signals. We found that treatment with the Taf6 AS1 oligonucleotide resulted in nearly â¼10 fold more cells with TAF6Î´ staining compared to control treated cells (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>). As a further control of specificity, oligonucleotide Bcl-x AS was transfected and caused no increase in nuclear TAF6Î´ immunofluorescent staining (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>). We conclude that TAF6Î´ protein in discrete nuclear loci is significantly increased by SSO targeting of the TAF6 pre-mRNA.</p>
        <fig id="pone-0002721-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0002721.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Specific induction of TAF6Î´ protein expression by modified antisense RNA oligonucleotides.</title>
            <p>(A) HeLa cells were transfected with splice site-switching oligonucleotides directed against exon IIÎ± of the TAF6 gene and treated with MG-132 5 hours later. 21 hours post transfection cells were fixed and stained with the indicated antibodies for immunocytochemistry (B) Quantification of endogenous TAF6Î´ expressing cells transfected with splice site-switching antisense oligonucleotides. Results are expressed as the percentage of cells displaying a clear TAF6Î´ punctate staining on a total of at least 500 cells. (C) Translation of exogenous TAF6Î´ is induced by modified antisense RNA oligonucleotides. Schematic representation of plasmid pASTAF6 containing sequences derived from the TAF6 cDNA (white) or from genomic DNA (grey). HeLa cells were first transfected with pASTAF6 and 19 hours later with splice site switching oligonucleotides and treated with MG132 and ZVAD-FMK 6 hours after this second transfection. 38 hours post-transfection protein extracts from cells were analyzed by immunoblotting with monoclonal antibodies directed against TFIID subunits.</p>
          </caption>
          <graphic xlink:href="pone.0002721.g002"/>
        </fig>
        <p>Immunofluorescence experiments measure the levels of detectable antigen in fixed cells. Since the levels of total cellular protein can potentially differ from the antigenically recognizable levels of protein we employed immunoblotting under denaturing conditions to directly examine the effect of TAF6Î´-inducing oligonucleotides on the translation of the TAF6Î´ mRNA in treated cells. Endogenous TAF6Î´ is undetectable by Western blotting of extracts from HeLa cell due to its rapid turnover by the proteasome (data not shown) and by caspase-dependent cleavage in apoptotic cells <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. We therefore developed a <italic>TAF6</italic> minigene plasmid that is responsive to SSO (pASTAF6, <xref ref-type="fig" rid="pone-0002721-g002">Fig. 2C</xref>). Immunoblots on total protein extracts from HeLa cells transfected with the spliceable minigene construct and later treated with TAF6Î´-inducing oligonucleotides resulted in a marked increase in TAF6Î´ protein levels, with a corresponding reduction in TAF6Î± (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2C</xref>). The levels of two other TFIID subunits, TAF5 and TBP, remained relatively constant. These data demonstrate a selective induction of TAF6Î´ translation and concomitant reduction in TAF6Î± levels by TAF6Î´-inducing SSOs.</p>
      </sec>
      <sec id="s3c">
        <title>Endogenous TAF6Î´ expression causes apoptosis in HeLa cells</title>
        <p>We next investigated the physiological consequences of SSO-induced endogenous TAF6Î´ expression in HeLa cells. The transfection of HeLa cells with a scrambled antisense oligonucleotide resulted in no obvious morphological changes or changes in cell number when visualized by light microscopy (<xref ref-type="fig" rid="pone-0002721-g003">Fig. 3A</xref>, left image). In stark contrast, TAF6Î´-inducing SSO resulted in an obvious loss of adherent cells and produced significant numbers of cells that exhibit the classical features of apoptosis, including membrane blebbing (<xref ref-type="fig" rid="pone-0002721-g003">Fig. 3A</xref>, right image). To obtain further evidence that TAF6Î´ induction causes apoptosis we measured cleavage of the well-known caspase substrate PARP-1, since activation of the caspase protease cascade is a defining biochemical feature of apoptosis. Immunoblotting revealed readily detectable cleavage of PARP-1 in cells when TAF6Î´ was induced (<xref ref-type="fig" rid="pone-0002721-g003">Fig. 3B</xref>, lane 2). As an additional control for the specificity of the Taf6 AS1 oligonucleotide, we used a Bcl-xS-inducing SSO. Consistent with a previous report <xref rid="pone.0002721-Mercatante2" ref-type="bibr">[47]</xref>, the induction of Bcl-xS expression has little effect on apoptosis in HeLa cells (<xref ref-type="fig" rid="pone-0002721-g003">Fig. 3B</xref>, lane 3). To further substantiate and quantify TAF6Î´-induced apoptosis we employed flow cytometry to measure the levels of caspase-cleaved cytokeratin-18 (KRT18c), another established marker of apoptosis <xref rid="pone.0002721-Leers1" ref-type="bibr">[48]</xref>. Treatment of HeLa cells with the Taf6 AS1 oligonucleotide resulted in a 3.5 fold increase in KRT18c positive cells (<xref ref-type="fig" rid="pone-0002721-g003">Fig. 3C</xref>). As an independent quantification of apoptosis, we employed flow cytometry to measure the level of Sub-G1 DNA content. This assay showed that TAF6Î´ induction resulted in a 2.8 fold increase in apoptosis whereas Bcl-xS induction resulted in a 1.3 fold increase in apoptosis in HeLa cells (<xref ref-type="fig" rid="pone-0002721-g003">Fig. 3D</xref>). Thus, four distinct assays show that the induction of endogenous TAF6Î´ triggers a robust apoptotic response in HeLa cells.</p>
        <fig id="pone-0002721-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0002721.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Expression of endogenous TAF6Î´ causes cell death by apoptosis.</title>
            <p>HeLa cells were transfected with antisense oligonucleotides that induce endogenous TAF6Î´ (Taf6 AS1), scrambled control oligonucleotides (Control AS), or oligonucleotides that induce endogenous Bcl-xS expression (Bcl-x AS). (A) 24 hours post transfection cells were observed by differential interference contrast microscopy. (B) Proteins were extracted from transfected cells and subjected to immunoblot analysis with anti-PARP monoclonal antibodies. PARPc indicates caspase cleaved PARP. (C) The percentage of apoptotic cells was analyzed by flow cytometry using monoclonal antibodies that detect caspase cleaved cytokeratin-18. (D) The percentage of apoptotic cells was analyzed by flow cytometry to detect sub G1 DNA content. The values indicated above the data bars are the fold induction of apoptosis with respect to Control oligonucleotide-treated cells.</p>
          </caption>
          <graphic xlink:href="pone.0002721.g003"/>
        </fig>
      </sec>
      <sec id="s3d">
        <title>TAF6Î´ induces apoptosis in the absence of p53</title>
        <p>The tumor suppressor p53 interacts physically and functionally with TAF6Î± (see <xref ref-type="sec" rid="s1">Introduction</xref>). Mutations in the p53 pathway are thought to allow human tumor cells to escape apoptotic death and therefore allow cancer development <xref rid="pone.0002721-Vousden1" ref-type="bibr">[6]</xref>. It was therefore of fundamental importance to establish whether TAF6Î´-induced apoptosis can occur in the absence of p53. To address whether TAF6Î´-dependent apoptosis requires p53 we transfected the Saos-2 osteosarcoma cell line that is devoid of a functional <italic>p53</italic> gene <xref rid="pone.0002721-Masuda1" ref-type="bibr">[49]</xref> with oligonucleotide Taf6 AS1. Transfection of Taf6 AS1, but not Bcl-x AS into Saos-2 cells effectively increased endogenous TAF6Î´ mRNA levels (<xref ref-type="fig" rid="pone-0002721-g004">Fig. 4A</xref>, lane 3). Analysis of the RT-PCR results showed an approximately â¼5 fold induction in the TAF6Î´/TAF6Î±+Î´ mRNA ratio (<xref ref-type="fig" rid="pone-0002721-g004">Fig. 4B</xref>). The expression of TAF6Î´ induced a 3.3 fold increase in apoptosis in Saos-2 as measured by Sub-G1 DNA content (<xref ref-type="fig" rid="pone-0002721-g004">Fig. 4C</xref>). Similar results were obtained in another cell line (H1299 lung carcinoma) that does not contain p53 (data not shown). Because HeLa cells have impaired p53 function due to the expression of the Human Papilloma Virus E6 gene product <xref rid="pone.0002721-May1" ref-type="bibr">[50]</xref>, we also compared the efficiency of induction of apoptosis in the A549 lung carcinoma cells because they express wild type p53. Taf6 AS1 transfection increased apoptosis by 3.1 fold (<xref ref-type="fig" rid="pone-0002721-g004">Fig. 4D</xref>), whereas Bcl-x AS transfection caused no increase in apoptosis over background levels (<xref ref-type="fig" rid="pone-0002721-g004">Fig. 4D</xref>). The fact that Saos-2 are at least as susceptible as A549 cells to TAF6Î´-induced programmed cell death was further verified by measuring PARP-1 cleavage by immunoblotting (<xref ref-type="fig" rid="pone-0002721-g004">Fig. 4E</xref> versus 4F). To reinforce the fact that p53 is dispensable for TAF6Î´-induced apoptosis, we employed the HCT-116 human colon carcinoma cell line and its isogenic counterpart HCT-116 p53 â/â in which the p53 gene has been deleted by homologous recombination <xref rid="pone.0002721-Bunz1" ref-type="bibr">[51]</xref>. The induction of apoptosis by TAF6Î´ in isogenic cells lacking p53 is equally robust as in wild-type cells, as judged by significant increases in both caspase-cleavage of cytokeratin-18 (<xref ref-type="fig" rid="pone-0002721-g005">Fig. 5B</xref>) and Sub-G1 DNA content (<xref ref-type="fig" rid="pone-0002721-g005">Fig. 5C</xref>). The induction of TAF6Î´ protein levels by the SSO strategy was efficient in both cells lines (<xref ref-type="fig" rid="pone-0002721-g005">Fig. 5A</xref>). The results demonstrate that p53 is dispensable for TAF6Î´-induced cell death. We conclude that TAF6Î´ controls apoptosis irrespective of cellular p53 status.</p>
        <fig id="pone-0002721-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0002721.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>TAF6Î´ induces apoptosis in cancer cell lines lacking p53.</title>
            <p>Saos-2 human bone osteosarcoma cells, that do not express p53, were transfected with antisense oligonucleotides that induce endogenous TAF6Î´ (Taf6 AS1), scrambled control oligonucleotides (Control AS), or oligonucleotides that induce endogenous Bcl-xS expression (Bcl-x AS). (A) 24 hours post transfection total RNA was isolated for analysis by RT-PCR with primers that amplify both the TAF6Î± and TAF6Î´ mRNAs. (B) RT-PCR products were analyzed on an Agilent Bioanalyzer. Error bars indicate the standard deviation of three independent transfections. (C) Percentage of apoptotic Saos-2 cells was analyzed by flow cytometry to detect sub G1 DNA content. Error bars indicate the standard deviation of three independent transfections. (D) As in C except that A549 human lung carcinoma cells, that express wild-type p53, were transfected. (E) As in C except that proteins were extracted from transfected Saos-2 cells and subjected to immunoblot analysis with anti-PARP monoclonal antibodies. PARPc indicates caspase cleaved PARP. (F) As in E except with A549 cells.</p>
          </caption>
          <graphic xlink:href="pone.0002721.g004"/>
        </fig>
        <fig id="pone-0002721-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0002721.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>p53 is dispensable for TAF6Î´-induced apoptosis.</title>
            <p>(A) Western blot analysis of TFIID subunits following TAF6 and Bcl-x SSO in HCT-116 p53 +/+ (left panels) and HCT-116 p53 â/â cells (right panels). HCT-116 cells were transfected first with plasmid pASTAF6 (see <xref ref-type="fig" rid="pone-0002721-g002">Fig. 2C</xref>) and 19 hours later with antisense oligonucleotides that induce endogenous TAF6Î´ (Taf6 AS1), scrambled control oligonucleotides (Control AS), or oligonucleotides that induce endogenous Bcl-xS expression (Bcl-x AS). Total cells extracts were prepared and separated on 10% SDS-PAGE, followed by immunoblotting with anti-TFIID subunit antibodies as indicated with arrows. (B) The percentage of apoptotic cells was analyzed by flow cytometry using monoclonal antibodies that detect caspase cleaved cytokeratin-18. (C) The percentage of apoptotic cells was analyzed by flow cytometry to detect sub G1 DNA content. The values indicated above the data bars are the fold induction of apoptosis with respect to Control oligonucleotide-treated cells. Error bars indicate the standard deviation of three independent transfections.</p>
          </caption>
          <graphic xlink:href="pone.0002721.g005"/>
        </fig>
      </sec>
      <sec id="s3e">
        <title>TAF6Î´ activates gene expression independently of p53</title>
        <p>TAF6Î´ can induce apoptosis of several cancer cell lines independent of their p53 status. We have previously shown that TAF6Î´ can bind the TFIID subunits TAF1, TAF5, TBP and TAF12 <italic>in vitro</italic>, and forms a TFIID-like complex that contains several TAFs but lacks TAF9 (TFIIDÏ) <italic>in vivo</italic>
<xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. <italic>TAF6</italic> is an essential gene that plays a broad role in the regulation of transcription programs (see <xref ref-type="sec" rid="s1">Introduction</xref>). To investigate whether TAF6Î´ can regulate transcription, with an emphasis on potentially p53-independent transcription, we employed genome-wide microarray technology. The transcriptional effects of TAF6Î´ are technically difficult to measure because endogenous TAF6Î´ is not induced in all cells during antisense transfection (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>) and because endogenous TAF6Î´-expressing cells are lost rapidly from the culture by apoptosis (<xref ref-type="fig" rid="pone-0002721-g003">Fig. 3</xref>). In order to achieve maximal sensitivity we chose a recently developed microarray technology based on chemiluminescent detection and longer oligonucleotide probes (60 nucleotides), that has been shown to provide increased signal dynamic range and higher sensitivity when compared to traditional microarray technologies <xref rid="pone.0002721-Noth3" ref-type="bibr">[52]</xref>, <xref rid="pone.0002721-Wang2" ref-type="bibr">[53]</xref>. The microarrays used represent 27,868 annotated human genes (<xref ref-type="sec" rid="s2">Material and Methods</xref>).</p>
        <p>The design of the microarray experiments enables detection of direct TAF6Î´ target genes without excluding potentially informative rapid secondary changes in mRNA levels. Wild-type HCT-116 and their p53-null isogenic counterparts (HCT-116 p53 â/â) were transfected with oligonucleotides Taf6 AS2 and Control AS, and total RNA was isolated and subjected to microarray analysis after 24 hours. The scrambled control oligonucleotide was employed as a reference to exclude any non-specific changes in gene expression due to the transfection protocol or the introduction of exogenous oligonucleotide into cells. Biological triplicates (three independent transfections) were performed for each condition and statistical analysis and filtering was performed, as detailed in <xref ref-type="sec" rid="s2">Materials and Methods</xref>, to identify significantly (P&lt;0.05) regulated mRNAs.</p>
        <p>The induction of endogenous TAF6Î´ in wild-type HCT-116 cells resulted in significant changes in the levels of 321 mRNAs out of a total of 27,868 independent genes measured by microarray analysis (<xref ref-type="fig" rid="pone-0002721-g006">Fig. 6A</xref>). The induction of endogenous TAF6Î´ in HCT-116 lacking p53 expression resulted in significant changes in the levels of 444 mRNAs. In both cells the majority of mRNAs are increased in response to TAF6Î´. These data establish that TAF6Î´ acts primarily as a positive regulator of gene expression and rule out the possibility that TAF6Î´-induced cell death is a result of a global reduction in mRNA transcription.</p>
        <fig id="pone-0002721-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0002721.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>Endogenous TAF6Î´ expression induces apoptosis in the absence of p53.</title>
            <p>(A) Transcriptome analysis following TAF6 SSO in HCT-116 p53+/+ and p53â/â cells. Expression levels of mRNAs from cells treated with oligonucleotide Taf6AS2 were individually compared to control oligonucleotide-treated HCT-116 samples by genome-wide microarray analysis. The absolute number of probes detecting statistically significant (p&lt;0.05) up- or down-regulation following splice-site selection is shown to the left of each bar; the maximum positive or negative logarithmic (base two) fold-change is shown to the right. The red gradient indicates positive, and the blue gradient negative fold changes in expression. (B) Transcriptome analysis following TAF6 SSO in HCT-116 cells and selecting for those genes that show significant regulation between the HCT-116 p53 +/+ versus HCT-116 p53 â/â cells irrespective of TAF6Î´ expression. Labels as in (A). (C) Venn-Diagram displaying the overlap between the three different target gene repertoires shown in (A) and (B). (D) Verification of gene expression changes by quantitative real-time RT-PCR. HCT-116 p53+/+ and HCT-116 p53â/â cells were transfected with two distinct antisense oligonucleotides that induce endogenous TAF6Î´; Taf6 AS1 (grey bars), Taf6 AS2 (black bars). White bars indicate values from microarray experiments for comparison. 18 hours post-transfection total RNA was extracted and the levels of the indicated mRNAs were analyzed by quantitative real-time PCR with respect to the levels from cells treated with the control oligonucleotide. Error bars indicate standard deviation of three independent transfections.</p>
          </caption>
          <graphic xlink:href="pone.0002721.g006"/>
        </fig>
        <p>TAF6Î± physically interacts with p53 <xref rid="pone.0002721-Thut1" ref-type="bibr">[34]</xref>, yet TAF6Î´ induces apoptosis in cells lacking p53. We therefore analyzed the microarray data to determine whether TAF6Î´ can control gene expression independently of p53. The p53-dependent genes were identified by filtering for genes that are significantly changed in the wild-type HCT-116 versus HCT-116 p53 â/â in both the presence of the TAF6 SSO or a scrambled control oligonucleotide (<xref ref-type="fig" rid="pone-0002721-g006">Fig. 6B</xref>). As expected, well-established p53 target genes, including FAS <xref rid="pone.0002721-OwenSchaub1" ref-type="bibr">[54]</xref>, FDXR <xref rid="pone.0002721-Hwang1" ref-type="bibr">[8]</xref>, SESN1 <xref rid="pone.0002721-Kunz1" ref-type="bibr">[55]</xref> and p21/CDKN1A <xref rid="pone.0002721-elDeiry1" ref-type="bibr">[56]</xref> were found in the p53-dependent gene set (Supplementary <xref ref-type="supplementary-material" rid="pone.0002721.s004">Data File S3</xref>), confirming the sensitivity and accuracy of the microarray methodology. We focused on the identification of genes regulated in both wild-type HCT-116 and HCT-116 p53 â/â because these mRNAs represent candidates for genes that function to induce p53-independent apoptosis. The different gene sets significantly regulated by TAF6Î´ in wild-type and p53 negative HCT-116 cells, as well as the p53-dependent genes, are shown by Venn diagrams in <xref ref-type="fig" rid="pone-0002721-g006">Fig. 6C</xref>. The absolute numbers of TAF6Î´-dependent genes is underestimated when compared to p53-dependent genes because the two gene sets are derived from very technically different approaches. p53-dependence is defined here through the use of an isogenic cell line in which p53 expression is eliminated completely in 100% of cells by genetic ablation through homologous recombination. In contrast TAF6Î´-dependency is defined by the induction of endogenous TAF6Î´ via transient transfection with splice switching oligonucleotides, that occurs only partially (<xref ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref>) and in fraction of the cells (<xref ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>). Nonetheless, the analysis revealed 21 TAF6Î´-dependent, p53-independent genes (<xref ref-type="fig" rid="pone-0002721-g006">Fig. 6C</xref>). To independently validate the TAF6Î´-dependent genes we selected 4 genes (and the internal control FNBP4) for real-time quantitative RT-PCR analysis. One gene (HOM-TES-103) is within our P-value cut-of (P&lt;0.05), another (ACRC) is slightly outside the P-value cut-off (Pâ=â0.0698), and a third (HES1) substantially outside our cutoff (Pâ=â0.2012). ACRC, HES1 and HOM-TES-103 were induced by TAF6Î´ in wild-type p53 HCT-116 cells as well as HCT-116 p53 â/â cells (<xref ref-type="fig" rid="pone-0002721-g006">Fig. 6D</xref>). We also verified the expression of ATF3, since it represents the distinct class of genes that are regulated by TAF6Î´ only in the presence of p53. ATF3 induction was documented in HCT-116 cells expressing p53 but not in p53-null HCT-116 cells, as validated by real-time RT-PCR (<xref ref-type="fig" rid="pone-0002721-g006">Fig. 6D</xref>). To reinforce the specificity of all of these effects, we employed two distinct TAF6Î´-inducing SSOs, both of which caused comparable changes in expression of the four genes tested (<xref ref-type="fig" rid="pone-0002721-g006">Fig. 6D</xref>). These results confirm that TAF6Î´ can induce gene expression independently of the tumor suppressor p53.</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>Here we have combined <underline>s</underline>plice-<underline>s</underline>witching <underline>o</underline>ligonucleotides (SSOs) with high-sensitivity genome-wide microarrays to shed light on the function of endogenous TAF6Î´. By experimentally inducing endogenous TAF6Î´ expression we show that TAF6Î´ triggers robust cell death in several cancer cell types. The expression of the p53 tumor suppressor is dispensable for TAF6Î´-dependent cell death and gene expression in several cell lines. The data establish the TAF6Î´ pathway as an important signaling hub that can control apoptosis in the absence of p53. Our microarray results show that TAF6Î´ expression activates genes, such as HOM-TES-103, HES1 and ACRC independently of p53. The 21 genes we identify here that are controlled by TAF6Î´ independently of p53 represent candidate genes that could mediate TAF6Î´-dependent apoptosis. The majority of genes identified through the unbiased microarray approach are of as yet unknown biological function; a finding that is not unexpected given that TAF6Î´ represents a newly discovered signaling pathway. Therefore, further work will be required to determine their contributions to the apoptotic program. Given the fact that TAF6Î´ activates minimally hundreds of genes, it is improbable that any single gene product could account fully for TAF6Î´-driven apoptosis. The microarray data presented here represent, to our knowledge, the first documentation of changes in gene expression due to induction of an endogenous TFIID subunit. Based on the increases in gene expression we have demonstrated here, we propose a model in which TAF6Î´ drives a pro-apoptotic transcription program to initiate the apoptotic cascade.</p>
      <p>Despite intensive efforts, the molecular mechanisms by which the TAFs specifically influence gene expression remain obscure. The advantage of the SSO strategy employed here is that it reveals for the first time a pro-apoptotic role for endogenous TAF6Î´ levels. As is the case for all physiological alternative splicing events, the TAF6Î´ isoform is produced with a concomitant reduction in the levels of the major alpha isoform. The reduction in TAF6Î± may contribute to changes in gene expression during the SSO-enforced as well as the normal physiological switch from alpha to delta expression. It is, however, important to note that the overexpression of TAF6Î´ alone is sufficient to induce apoptosis in cells that express endogenous TAF6Î± <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. Therefore, although decreased TAF6Î± expression necessarily accompanies increased TAF6Î´ expression, all the available evidence indicates that the increase of the minor TAF6Î´ isoform is a critical molecular event triggering apoptosis.</p>
      <p>Mounting evidence suggests that functionally distinct forms of TFIID exist <xref rid="pone.0002721-Muller2" ref-type="bibr">[57]</xref>, and that TFIID composition is dynamic <xref rid="pone.0002721-Gegonne1" ref-type="bibr">[58]</xref>. Recently, the dynamic nature of core promoter recognition complexes <italic>in vivo</italic> has been underscored by the observation of a drastic replacement of the cellular pools of canonical TFIID with a complex containing TRF3/TAF3 during myogenesis <xref rid="pone.0002721-Deato1" ref-type="bibr">[59]</xref>. The number of combinatorial possibilities for more subtle changes within the TFIID complex itself continues to expand with the discovery of new TAF isoforms; TAF4 and TAF4b possess distinct target gene specificities <xref rid="pone.0002721-Mengus1" ref-type="bibr">[60]</xref>, TAF9 and TAF9b can both incorporate into TFIID but are functionally non-redundant <xref rid="pone.0002721-Frontini1" ref-type="bibr">[61]</xref>, and TAF1-2 and TAF1-4 are signal-inducible and functionally distinct splice variants of TAF1 <xref rid="pone.0002721-Katzenberger1" ref-type="bibr">[62]</xref>, <xref rid="pone.0002721-Metcalf1" ref-type="bibr">[63]</xref>. To date, however, the functional consequences for changes in the cellular levels of endogenous TFIID subunits have remained unknown. The current findings show that the induction of a single TFIID subunit within living cells can orchestrate gene expression programs to alter cell physiology. TAF6Î´ mRNA levels can be dramatically induced in HL-60 cells after differentiation by retinoic-acid, demonstrating at least one physiological situation where TAF6Î´ is induced in living cells <xref rid="pone.0002721-Bell2" ref-type="bibr">[39]</xref>. Recent genetic evidence that TAF12 is required for ethylene-responsive transcription in plants <xref rid="pone.0002721-Robles1" ref-type="bibr">[64]</xref> further argues that TFIID is a signal-responsive transcription factor. Therefore, in addition to its known functions in core promoter recognition and co-activation, TFIID represents a platform that integrates cellular signals with the control of gene expression.</p>
      <p>The pro-apoptotic transcription factor p53 plays a central role in genome surveillance and tumor suppression. The p53 protein is not required for cell viability and indeed is lost or mutated in roughly 50% of tumors <xref rid="pone.0002721-Vousden1" ref-type="bibr">[6]</xref>. Even in animal models where functional p53 can be restored by gene therapy, tumors readily attain resistance to p53 due to inactivation of p19<italic><sup>ARF</sup></italic> or p53 itself <xref rid="pone.0002721-Martins1" ref-type="bibr">[65]</xref>. The efficient induction of cell death in several different tumor cell lines by SSO targeting of <italic>TAF6</italic>, independent of their p53 status, provides a proof-of-principle that the TAF6Î´ pathway can be exploited to kill tumor cells. The data presented here define the TAF6Î´ signaling hub as able to control apoptosis without p53, but with interconnections to the p53 pathway including several shared target genes, as revealed by transcriptome-wide microarray analysis (<xref ref-type="fig" rid="pone-0002721-g006">Fig. 6B</xref>). Unlike p53, TAF6 is essential for viability in all organisms studied <xref rid="pone.0002721-Poon1" ref-type="bibr">[26]</xref>, <xref rid="pone.0002721-Lago1" ref-type="bibr">[27]</xref>, <xref rid="pone.0002721-Aoyagi1" ref-type="bibr">[28]</xref>, <xref rid="pone.0002721-Amsterdam1" ref-type="bibr">[29]</xref>. Furthermore, targeting <italic>TAF6</italic> results in a substantially more robust apoptotic response than targeting another apoptotic gene, <italic>Bcl-x</italic> in several tumor cell lines (<xref ref-type="fig" rid="pone-0002721-g003">Fig.s 3</xref>, <xref ref-type="fig" rid="pone-0002721-g004">4</xref> &amp; <xref ref-type="fig" rid="pone-0002721-g005">5</xref>). Further characterization of the TAF6Î´ signaling hub may therefore provide novel therapeutic avenues to induce controlled tumor cell death irrespective of their p53 status.</p>
      <p>The TAF6Î´ pathway remains an orphan pathway since the precise molecular trigger that induces TAF6Î´ expression in the physiological context is currently unknown. The fact that TAF6Î´ can act downstream of p53 to control gene expression, and that TAF6Î´ can dictate cell death versus life decisions of human cells, evoke the possibility that this newly defined pathway could be subject to deregulation in certain cancer cells. In this light, it is intriguing that expression levels of TAF6 have been correlated with the inflammatory breast cancer phenotype <xref rid="pone.0002721-Dressman1" ref-type="bibr">[66]</xref>, and isoform specific enrichment of a TAF6 splicing variant has been reported in breast cancer <xref rid="pone.0002721-Wang1" ref-type="bibr">[45]</xref>. Experiments to identify the upstream signals that control TAF6Î´ expression <italic>in vivo</italic> in healthy tissues, as well as to uncover the potential role of mutations to the TAF6Î´ pathway in cancer are ongoing in our laboratory.</p>
    </sec>
    <sec sec-type="supplementary-material" id="s5">
      <title>Supporting Information</title>
      <supplementary-material content-type="local-data" id="pone.0002721.s001">
        <label>Figure S1</label>
        <caption>
          <p>(A) Time course for antisense RNA-mediated TAF6Î´ mRNA induction. Transfections and RT-PCR were performed as in <xref ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref> except that RNA was extracted at various times (x-axis) after transfection. (B) Dose-dependent antisense mediated induction of TAF6Î´ mRNA expression. As in B, with different concentrations of oligonucleotides transfected indicated on the x-axis.</p>
          <p>(0.71 MB EPS)</p>
        </caption>
        <media xlink:href="pone.0002721.s001.eps">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0002721.s002">
        <label>Supplementary Data File S1</label>
        <caption>
          <p>Genes changing in response TAF6delta in HCT-116 p53 +/+ cells</p>
          <p>(0.05 MB TXT)</p>
        </caption>
        <media xlink:href="pone.0002721.s002.txt">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0002721.s003">
        <label>Supplementary Data File S2</label>
        <caption>
          <p>Genes changing in response to TAF6delta in HCT-116 p53 â/â</p>
          <p>(0.07 MB TXT)</p>
        </caption>
        <media xlink:href="pone.0002721.s003.txt">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0002721.s004">
        <label>Supplementary Data File S3</label>
        <caption>
          <p>Genes differentially expressed in the HCT-116 p53 +/+ cells versus in HCT-116 p53 â/â cells both in cells treated with control oligonucleotide and TAF6delta -inducing oligonucleotides</p>
          <p>(0.24 MB TXT)</p>
        </caption>
        <media xlink:href="pone.0002721.s004.txt">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0002721.s005">
        <label>Supplementary Data File S4</label>
        <caption>
          <p>Genes differentially regulated by TAF6delta in both HCT-116 p53 +/+ cells and HCT-116 p53 â/â cells</p>
          <p>(0.01 MB TXT)</p>
        </caption>
        <media xlink:href="pone.0002721.s005.txt">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank B. Vogelstein for providing HCT-116 p53 â/â cells. We are grateful to B. Chabot for critical reading of the manuscript and to L. Tora for anti-TAF antibodies.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding: </bold>F.X.P. is recipient of a doctoral fellowship from the Nausicaa Combat Sa LeucÃ©mie association. A.B.'s group received funds from the European Hematology Association - JosÃ© Carreras Foundation, and the French Ministry of Research through the âComplexitÃ© du Vivant - Action STICS-SantÃ©â program. Work in B.B.'s laboratory was funded through a Discovery grant from Natural Sciences and Engineering Research Council of Canada. B.B. holds the Canada Research Chair in Genomic Regulation.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="pone.0002721-Hengartner1">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hengartner</surname><given-names>MO</given-names></name></person-group>
<year>2000</year>
<article-title>The biochemistry of apoptosis.</article-title>
<source>Nature</source>
<volume>407</volume>
<fpage>770</fpage>
<lpage>776</lpage>
<pub-id pub-id-type="pmid">11048727</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Thompson1">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>
<year>1995</year>
<article-title>Apoptosis in the pathogenesis and treatment of disease.</article-title>
<source>Science</source>
<volume>267</volume>
<fpage>1456</fpage>
<lpage>1462</lpage>
<pub-id pub-id-type="pmid">7878464</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Fesus1">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fesus</surname><given-names>L</given-names></name></person-group>
<year>1999</year>
<article-title>Inducible gene expression in apoptosis [In Process Citation].</article-title>
<source>Cell Death Differ</source>
<volume>6</volume>
<fpage>1144</fpage>
<lpage>1145</lpage>
<pub-id pub-id-type="pmid">10637428</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Kumar1">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Cakouros</surname><given-names>D</given-names></name></person-group>
<year>2004</year>
<article-title>Transcriptional control of the core cell-death machinery.</article-title>
<source>Trends Biochem Sci</source>
<volume>29</volume>
<fpage>193</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">15082313</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Schwerk1">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwerk</surname><given-names>C</given-names></name><name><surname>Schulze-Osthoff</surname><given-names>K</given-names></name></person-group>
<year>2005</year>
<article-title>Regulation of apoptosis by alternative pre-mRNA splicing.</article-title>
<source>Mol Cell</source>
<volume>19</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">15989960</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Vousden1">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name></person-group>
<year>2007</year>
<article-title>p53 in health and disease.</article-title>
<source>Nat Rev Mol Cell Biol</source>
<volume>8</volume>
<fpage>275</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="pmid">17380161</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Liu1">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group>
<year>2002</year>
<article-title>The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis.</article-title>
<source>Oncogene</source>
<volume>21</volume>
<fpage>7195</fpage>
<lpage>7204</lpage>
<pub-id pub-id-type="pmid">12370809</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Hwang1">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>PM</given-names></name><name><surname>Bunz</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.</article-title>
<source>Nat Med</source>
<volume>7</volume>
<fpage>1111</fpage>
<lpage>1117</lpage>
<pub-id pub-id-type="pmid">11590433</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Yu1">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Hwang</surname><given-names>PM</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group>
<year>2001</year>
<article-title>PUMA induces the rapid apoptosis of colorectal cancer cells.</article-title>
<source>Mol Cell</source>
<volume>7</volume>
<fpage>673</fpage>
<lpage>682</lpage>
<pub-id pub-id-type="pmid">11463391</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Oda1">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oda</surname><given-names>E</given-names></name><name><surname>Ohki</surname><given-names>R</given-names></name><name><surname>Murasawa</surname><given-names>H</given-names></name><name><surname>Nemoto</surname><given-names>J</given-names></name><name><surname>Shibue</surname><given-names>T</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.</article-title>
<source>Science</source>
<volume>288</volume>
<fpage>1053</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="pmid">10807576</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Miyashita1">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyashita</surname><given-names>T</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group>
<year>1995</year>
<article-title>Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.</article-title>
<source>Cell</source>
<volume>80</volume>
<fpage>293</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">7834749</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Oda2">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oda</surname><given-names>K</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Tanikawa</surname><given-names>C</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.</article-title>
<source>Cell</source>
<volume>102</volume>
<fpage>849</fpage>
<lpage>862</lpage>
<pub-id pub-id-type="pmid">11030628</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Bell1">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bell</surname><given-names>B</given-names></name><name><surname>Tora</surname><given-names>L</given-names></name></person-group>
<year>1999</year>
<article-title>Regulation of gene expression by multiple forms of TFIID and other novel TAFII-containing complexes.</article-title>
<source>Exp Cell Res</source>
<volume>246</volume>
<fpage>11</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">9882510</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Green1">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>MR</given-names></name></person-group>
<year>2000</year>
<article-title>TBP-associated factors (TAFIIs): multiple, selective transcriptional mediators in common complexes [In Process Citation].</article-title>
<source>Trends Biochem Sci</source>
<volume>25</volume>
<fpage>59</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">10664584</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Muller1">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>F</given-names></name><name><surname>Demeny</surname><given-names>MA</given-names></name><name><surname>Tora</surname><given-names>L</given-names></name></person-group>
<year>2007</year>
<article-title>New problems in RNA polymerase II transcription initiation: matching the diversity of core promoters with a variety of promoter recognition factors.</article-title>
<source>J Biol Chem</source>
<volume>282</volume>
<fpage>14685</fpage>
<lpage>14689</lpage>
<pub-id pub-id-type="pmid">17395580</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Albright1">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Albright</surname><given-names>S</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name></person-group>
<year>2000</year>
<article-title>TAFs revisited: more data reveal new twists and confirm old ideas.</article-title>
<source>Gene</source>
<volume>242</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">10721692</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Gangloff1">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gangloff</surname><given-names>YG</given-names></name><name><surname>Romier</surname><given-names>C</given-names></name><name><surname>Thuault</surname><given-names>S</given-names></name><name><surname>Werten</surname><given-names>S</given-names></name><name><surname>Davidson</surname><given-names>I</given-names></name></person-group>
<year>2001</year>
<article-title>The histone fold is a key structural motif of transcription factor TFIID.</article-title>
<source>Trends Biochem Sci</source>
<volume>26</volume>
<fpage>250</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="pmid">11295558</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Xie1">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Kokubo</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>SL</given-names></name><name><surname>Mirza</surname><given-names>UA</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Structural similarity between TAFs and the heterotetrameric core of the histone octamer [see comments].</article-title>
<source>Nature</source>
<volume>380</volume>
<fpage>316</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="pmid">8598927</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Werten1">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Werten</surname><given-names>S</given-names></name><name><surname>Mitschler</surname><given-names>A</given-names></name><name><surname>Romier</surname><given-names>C</given-names></name><name><surname>Gangloff</surname><given-names>YG</given-names></name><name><surname>Thuault</surname><given-names>S</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Crystal structure of a subcomplex of human transcription factor TFIID formed by TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 (hTAF(II)20).</article-title>
<source>J Biol Chem</source>
<volume>277</volume>
<fpage>45502</fpage>
<lpage>45509</lpage>
<pub-id pub-id-type="pmid">12237304</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Birck1">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Birck</surname><given-names>C</given-names></name><name><surname>Poch</surname><given-names>O</given-names></name><name><surname>Romier</surname><given-names>C</given-names></name><name><surname>Ruff</surname><given-names>M</given-names></name><name><surname>Mengus</surname><given-names>G</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Human TAF(II)28 and TAF(II)18 interact through a histone fold encoded by atypical evolutionary conserved motifs also found in the SPT3 family.</article-title>
<source>Cell</source>
<volume>94</volume>
<fpage>239</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">9695952</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Gangloff2">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gangloff</surname><given-names>YG</given-names></name><name><surname>Sanders</surname><given-names>SL</given-names></name><name><surname>Romier</surname><given-names>C</given-names></name><name><surname>Kirschner</surname><given-names>D</given-names></name><name><surname>Weil</surname><given-names>PA</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Histone folds mediate selective heterodimerization of yeast TAF(II)25 with TFIID components yTAF(II)47 and yTAF(II)65 and with SAGA component ySPT7.</article-title>
<source>Mol Cell Biol</source>
<volume>21</volume>
<fpage>1841</fpage>
<lpage>1853</lpage>
<pub-id pub-id-type="pmid">11238921</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Gangloff3">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gangloff</surname><given-names>YG</given-names></name><name><surname>Pointud</surname><given-names>JC</given-names></name><name><surname>Thuault</surname><given-names>S</given-names></name><name><surname>Carre</surname><given-names>L</given-names></name><name><surname>Romier</surname><given-names>C</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>The TFIID components human TAF(II)140 and Drosophila BIP2 (TAF(II)155) are novel metazoan homologues of yeast TAF(II)47 containing a histone fold and a PHD finger.</article-title>
<source>Mol Cell Biol</source>
<volume>21</volume>
<fpage>5109</fpage>
<lpage>5121</lpage>
<pub-id pub-id-type="pmid">11438666</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Wright1">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wright</surname><given-names>KJ</given-names></name><name><surname>Marr</surname><given-names>MT</given-names><suffix>2nd</suffix></name><name><surname>Tjian</surname><given-names>R</given-names></name></person-group>
<year>2006</year>
<article-title>TAF4 nucleates a core subcomplex of TFIID and mediates activated transcription from a TATA-less promoter.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>103</volume>
<fpage>12347</fpage>
<lpage>12352</lpage>
<pub-id pub-id-type="pmid">16895980</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Michel1">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Michel</surname><given-names>B</given-names></name><name><surname>Komarnitsky</surname><given-names>P</given-names></name><name><surname>Buratowski</surname><given-names>S</given-names></name></person-group>
<year>1998</year>
<article-title>Histone-like TAFs are essential for transcription in vivo.</article-title>
<source>Mol Cell</source>
<volume>2</volume>
<fpage>663</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="pmid">9844638</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Shen1">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>WC</given-names></name><name><surname>Bhaumik</surname><given-names>SR</given-names></name><name><surname>Causton</surname><given-names>HC</given-names></name><name><surname>Simon</surname><given-names>I</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Systematic analysis of essential yeast TAFs in genome-wide transcription and preinitiation complex assembly.</article-title>
<source>Embo J</source>
<volume>22</volume>
<fpage>3395</fpage>
<lpage>3402</lpage>
<pub-id pub-id-type="pmid">12840001</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Poon1">
        <label>26</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poon</surname><given-names>D</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Campbell</surname><given-names>AM</given-names></name><name><surname>Bjorklund</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Identification and characterization of a TFIID-like multiprotein complex from Saccharomyces cerevisiae.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>92</volume>
<fpage>8224</fpage>
<lpage>8228</lpage>
<pub-id pub-id-type="pmid">7667272</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Lago1">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lago</surname><given-names>C</given-names></name><name><surname>Clerici</surname><given-names>E</given-names></name><name><surname>Dreni</surname><given-names>L</given-names></name><name><surname>Horlow</surname><given-names>C</given-names></name><name><surname>Caporali</surname><given-names>E</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>The Arabidopsis TFIID factor AtTAF6 controls pollen tube growth.</article-title>
<source>Dev Biol</source>
<volume>285</volume>
<fpage>91</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">16039640</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Aoyagi1">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aoyagi</surname><given-names>N</given-names></name><name><surname>Wassarman</surname><given-names>DA</given-names></name></person-group>
<year>2001</year>
<article-title>Developmental and transcriptional consequences of mutations in Drosophila TAF(II)60.</article-title>
<source>Mol Cell Biol</source>
<volume>21</volume>
<fpage>6808</fpage>
<lpage>6819</lpage>
<pub-id pub-id-type="pmid">11564865</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Amsterdam1">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>A</given-names></name><name><surname>Nissen</surname><given-names>RM</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Swindell</surname><given-names>EC</given-names></name><name><surname>Farrington</surname><given-names>S</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Identification of 315 genes essential for early zebrafish development.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>101</volume>
<fpage>12792</fpage>
<lpage>12797</lpage>
<pub-id pub-id-type="pmid">15256591</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Purrello1">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Purrello</surname><given-names>M</given-names></name><name><surname>Di Pietro</surname><given-names>C</given-names></name><name><surname>Viola</surname><given-names>A</given-names></name><name><surname>Rapisarda</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>S</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Genomics and transcription analysis of human TFIID.</article-title>
<source>Oncogene</source>
<volume>16</volume>
<fpage>1633</fpage>
<lpage>1638</lpage>
<pub-id pub-id-type="pmid">9569032</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Weinzierl1">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinzierl</surname><given-names>RO</given-names></name><name><surname>Ruppert</surname><given-names>S</given-names></name><name><surname>Dynlacht</surname><given-names>BD</given-names></name><name><surname>Tanese</surname><given-names>N</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name></person-group>
<year>1993</year>
<article-title>Cloning and expression of Drosophila TAFII60 and human TAFII70 reveal conserved interactions with other subunits of TFIID.</article-title>
<source>Embo J</source>
<volume>12</volume>
<fpage>5303</fpage>
<lpage>5309</lpage>
<pub-id pub-id-type="pmid">8262073</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Burke1">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burke</surname><given-names>TW</given-names></name><name><surname>Kadonaga</surname><given-names>JT</given-names></name></person-group>
<year>1997</year>
<article-title>The downstream core promoter element, DPE, is conserved from Drosophila to humans and is recognized by TAFII60 of Drosophila.</article-title>
<source>Genes Dev</source>
<volume>11</volume>
<fpage>3020</fpage>
<lpage>3031</lpage>
<pub-id pub-id-type="pmid">9367984</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Shao1">
        <label>33</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shao</surname><given-names>H</given-names></name><name><surname>Revach</surname><given-names>M</given-names></name><name><surname>Moshonov</surname><given-names>S</given-names></name><name><surname>Tzuman</surname><given-names>Y</given-names></name><name><surname>Gazit</surname><given-names>K</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Core promoter binding by histone-like TAF complexes.</article-title>
<source>Mol Cell Biol</source>
<volume>25</volume>
<fpage>206</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="pmid">15601843</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Thut1">
        <label>34</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thut</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name><name><surname>Klemm</surname><given-names>R</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name></person-group>
<year>1995</year>
<article-title>p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.</article-title>
<source>Science</source>
<volume>267</volume>
<fpage>100</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">7809597</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Lu1">
        <label>35</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group>
<year>1995</year>
<article-title>Human TAFII31 protein is a transcriptional coactivator of the p53 protein.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>92</volume>
<fpage>5154</fpage>
<lpage>5158</lpage>
<pub-id pub-id-type="pmid">7761466</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Farmer1">
        <label>36</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farmer</surname><given-names>G</given-names></name><name><surname>Colgan</surname><given-names>J</given-names></name><name><surname>Nakatani</surname><given-names>Y</given-names></name><name><surname>Manley</surname><given-names>JL</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group>
<year>1996</year>
<article-title>Functional interaction between p53, the TATA-binding protein (TBP), andTBP-associated factors in vivo.</article-title>
<source>Mol Cell Biol</source>
<volume>16</volume>
<fpage>4295</fpage>
<lpage>4304</lpage>
<pub-id pub-id-type="pmid">8754830</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Jimenez1">
        <label>37</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>GS</given-names></name><name><surname>Nister</surname><given-names>M</given-names></name><name><surname>Stommel</surname><given-names>JM</given-names></name><name><surname>Beeche</surname><given-names>M</given-names></name><name><surname>Barcarse</surname><given-names>EA</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>A transactivation-deficient mouse model provides insights into Trp53 regulation and function.</article-title>
<source>Nat Genet</source>
<volume>26</volume>
<fpage>37</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">10973245</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Johnson1">
        <label>38</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>TM</given-names></name><name><surname>Hammond</surname><given-names>EM</given-names></name><name><surname>Giaccia</surname><given-names>A</given-names></name><name><surname>Attardi</surname><given-names>LD</given-names></name></person-group>
<year>2005</year>
<article-title>The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality.</article-title>
<source>Nat Genet</source>
<volume>37</volume>
<fpage>145</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="pmid">15654339</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Bell2">
        <label>39</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bell</surname><given-names>B</given-names></name><name><surname>Scheer</surname><given-names>E</given-names></name><name><surname>Tora</surname><given-names>L</given-names></name></person-group>
<year>2001</year>
<article-title>Identification of hTAF(II)80 delta links apoptotic signaling pathways to transcription factor TFIID function.</article-title>
<source>Mol Cell</source>
<volume>8</volume>
<fpage>591</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="pmid">11583621</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Mercatante1">
        <label>40</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mercatante</surname><given-names>DR</given-names></name><name><surname>Bortner</surname><given-names>CD</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name><name><surname>Kole</surname><given-names>R</given-names></name></person-group>
<year>2001</year>
<article-title>Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death.</article-title>
<source>J Biol Chem</source>
<volume>276</volume>
<fpage>16411</fpage>
<lpage>16417</lpage>
<pub-id pub-id-type="pmid">11278482</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Brou1">
        <label>41</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brou</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Scheer</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>C</given-names></name><etal/></person-group>
<year>1993</year>
<article-title>Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL- VP16 and the two nonacidic activation functions of the estrogen receptor.</article-title>
<source>Nucleic Acids Res</source>
<volume>21</volume>
<fpage>5</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">8441620</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Dubrovskaya1">
        <label>42</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dubrovskaya</surname><given-names>V</given-names></name><name><surname>Lavigne</surname><given-names>AC</given-names></name><name><surname>Davidson</surname><given-names>I</given-names></name><name><surname>Acker</surname><given-names>J</given-names></name><name><surname>Staub</surname><given-names>A</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Distinct domains of hTAFII100 are required for functional interaction with transcription factor TFIIF beta (RAP30) and incorporation into the TFIID complex.</article-title>
<source>Embo J</source>
<volume>15</volume>
<fpage>3702</fpage>
<lpage>3712</lpage>
<pub-id pub-id-type="pmid">8758937</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Noth1">
        <label>43</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noth</surname><given-names>S</given-names></name><name><surname>Brysbaert</surname><given-names>G</given-names></name><name><surname>Benecke</surname><given-names>A</given-names></name></person-group>
<year>2006</year>
<article-title>Normalization using weighted negative second order exponential error functions (NeONORM) provides robustness against asymmetries in comparative transcriptome profiles and avoids false calls.</article-title>
<source>Genomics Proteomics Bioinformatics</source>
<volume>4</volume>
<fpage>90</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">16970549</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Noth2">
        <label>44</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noth</surname><given-names>S</given-names></name><name><surname>Benecke</surname><given-names>A</given-names></name></person-group>
<year>2005</year>
<article-title>Avoiding inconsistencies over time and tracking difficulties in Applied Biosystems AB1700/Panther probe-to-gene annotations.</article-title>
<source>BMC Bioinformatics</source>
<volume>6</volume>
<fpage>307</fpage>
<pub-id pub-id-type="pmid">16372901</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Wang1">
        <label>45</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Nahta</surname><given-names>R</given-names></name><name><surname>Huper</surname><given-names>G</given-names></name><name><surname>Marks</surname><given-names>JR</given-names></name></person-group>
<year>2004</year>
<article-title>TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein.</article-title>
<source>Mol Cancer Res</source>
<volume>2</volume>
<fpage>442</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">15328371</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Taylor1">
        <label>46</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>JK</given-names></name><name><surname>Zhang</surname><given-names>QQ</given-names></name><name><surname>Wyatt</surname><given-names>JR</given-names></name><name><surname>Dean</surname><given-names>NM</given-names></name></person-group>
<year>1999</year>
<article-title>Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides [see comments].</article-title>
<source>Nat Biotechnol</source>
<volume>17</volume>
<fpage>1097</fpage>
<lpage>1100</lpage>
<pub-id pub-id-type="pmid">10545916</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Mercatante2">
        <label>47</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mercatante</surname><given-names>DR</given-names></name><name><surname>Mohler</surname><given-names>JL</given-names></name><name><surname>Kole</surname><given-names>R</given-names></name></person-group>
<year>2002</year>
<article-title>Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.</article-title>
<source>J Biol Chem</source>
<volume>277</volume>
<fpage>49374</fpage>
<lpage>49382</lpage>
<pub-id pub-id-type="pmid">12381725</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Leers1">
        <label>48</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leers</surname><given-names>MP</given-names></name><name><surname>Kolgen</surname><given-names>W</given-names></name><name><surname>Bjorklund</surname><given-names>V</given-names></name><name><surname>Bergman</surname><given-names>T</given-names></name><name><surname>Tribbick</surname><given-names>G</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Immunocytochemical detection and mapping of a cytokeratin 18 neo- epitope exposed during early apoptosis [In Process Citation].</article-title>
<source>J Pathol</source>
<volume>187</volume>
<fpage>567</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="pmid">10398123</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Masuda1">
        <label>49</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name><name><surname>Battifora</surname><given-names>H</given-names></name><name><surname>Cline</surname><given-names>MJ</given-names></name></person-group>
<year>1987</year>
<article-title>Rearrangement of the p53 gene in human osteogenic sarcomas.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>84</volume>
<fpage>7716</fpage>
<lpage>7719</lpage>
<pub-id pub-id-type="pmid">2823272</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-May1">
        <label>50</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>May</surname><given-names>E</given-names></name><name><surname>Jenkins</surname><given-names>JR</given-names></name><name><surname>May</surname><given-names>P</given-names></name></person-group>
<year>1991</year>
<article-title>Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene.</article-title>
<source>Oncogene</source>
<volume>6</volume>
<fpage>1363</fpage>
<lpage>1365</lpage>
<pub-id pub-id-type="pmid">1886712</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Bunz1">
        <label>51</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bunz</surname><given-names>F</given-names></name><name><surname>Dutriaux</surname><given-names>A</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Waldman</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Requirement for p53 and p21 to sustain G2 arrest after DNA damage.</article-title>
<source>Science</source>
<volume>282</volume>
<fpage>1497</fpage>
<lpage>1501</lpage>
<pub-id pub-id-type="pmid">9822382</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Noth3">
        <label>52</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noth</surname><given-names>S</given-names></name><name><surname>Brysbaert</surname><given-names>G</given-names></name><name><surname>Pellay</surname><given-names>FX</given-names></name><name><surname>Benecke</surname><given-names>A</given-names></name></person-group>
<year>2006</year>
<article-title>High-sensitivity transcriptome data structure and implications for analysis and biologic interpretation.</article-title>
<source>Genomics Proteomics Bioinformatics</source>
<volume>4</volume>
<fpage>212</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">17531797</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Wang2">
        <label>53</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Barbacioru</surname><given-names>C</given-names></name><name><surname>Hyland</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Hunkapiller</surname><given-names>KL</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays.</article-title>
<source>BMC Genomics</source>
<volume>7</volume>
<fpage>59</fpage>
<pub-id pub-id-type="pmid">16551369</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-OwenSchaub1">
        <label>54</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Owen-Schaub</surname><given-names>LB</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Cusack</surname><given-names>JC</given-names></name><name><surname>Angelo</surname><given-names>LS</given-names></name><name><surname>Santee</surname><given-names>SM</given-names></name><etal/></person-group>
<year>1995</year>
<article-title>Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.</article-title>
<source>Mol Cell Biol</source>
<volume>15</volume>
<fpage>3032</fpage>
<lpage>3040</lpage>
<pub-id pub-id-type="pmid">7539102</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Kunz1">
        <label>55</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kunz</surname><given-names>C</given-names></name><name><surname>Pebler</surname><given-names>S</given-names></name><name><surname>Otte</surname><given-names>J</given-names></name><name><surname>von der Ahe</surname><given-names>D</given-names></name></person-group>
<year>1995</year>
<article-title>Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.</article-title>
<source>Nucleic Acids Res</source>
<volume>23</volume>
<fpage>3710</fpage>
<lpage>3717</lpage>
<pub-id pub-id-type="pmid">7479001</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-elDeiry1">
        <label>56</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>el-Deiry</surname><given-names>WS</given-names></name><name><surname>Tokino</surname><given-names>T</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Levy</surname><given-names>DB</given-names></name><name><surname>Parsons</surname><given-names>R</given-names></name><etal/></person-group>
<year>1993</year>
<article-title>WAF1, a potential mediator of p53 tumor suppression.</article-title>
<source>Cell</source>
<volume>75</volume>
<fpage>817</fpage>
<lpage>825</lpage>
<pub-id pub-id-type="pmid">8242752</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Muller2">
        <label>57</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>F</given-names></name><name><surname>Tora</surname><given-names>L</given-names></name></person-group>
<year>2004</year>
<article-title>The multicoloured world of promoter recognition complexes.</article-title>
<source>Embo J</source>
<volume>23</volume>
<fpage>2</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">14685269</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Gegonne1">
        <label>58</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gegonne</surname><given-names>A</given-names></name><name><surname>Weissman</surname><given-names>JD</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Brady</surname><given-names>JN</given-names></name><name><surname>Singer</surname><given-names>DS</given-names></name></person-group>
<year>2006</year>
<article-title>TAF7: a possible transcription initiation check-point regulator.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>103</volume>
<fpage>602</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="pmid">16407123</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Deato1">
        <label>59</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deato</surname><given-names>MD</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name></person-group>
<year>2007</year>
<article-title>Switching of the core transcription machinery during myogenesis.</article-title>
<source>Genes Dev</source>
</element-citation>
      </ref>
      <ref id="pone.0002721-Mengus1">
        <label>60</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mengus</surname><given-names>G</given-names></name><name><surname>Fadloun</surname><given-names>A</given-names></name><name><surname>Kobi</surname><given-names>D</given-names></name><name><surname>Thibault</surname><given-names>C</given-names></name><name><surname>Perletti</surname><given-names>L</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>TAF4 inactivation in embryonic fibroblasts activates TGF beta signalling and autocrine growth.</article-title>
<source>Embo J</source>
<volume>24</volume>
<fpage>2753</fpage>
<lpage>2767</lpage>
<pub-id pub-id-type="pmid">16015375</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Frontini1">
        <label>61</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frontini</surname><given-names>M</given-names></name><name><surname>Soutoglou</surname><given-names>E</given-names></name><name><surname>Argentini</surname><given-names>M</given-names></name><name><surname>Bole-Feysot</surname><given-names>C</given-names></name><name><surname>Jost</surname><given-names>B</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>TAF9b (formerly TAF9L) is a bona fide TAF that has unique and overlapping roles with TAF9.</article-title>
<source>Mol Cell Biol</source>
<volume>25</volume>
<fpage>4638</fpage>
<lpage>4649</lpage>
<pub-id pub-id-type="pmid">15899866</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Katzenberger1">
        <label>62</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katzenberger</surname><given-names>RJ</given-names></name><name><surname>Marengo</surname><given-names>MS</given-names></name><name><surname>Wassarman</surname><given-names>DA</given-names></name></person-group>
<year>2006</year>
<article-title>ATM and ATR pathways signal alternative splicing of Drosophila TAF1 pre-mRNA in response to DNA damage.</article-title>
<source>Mol Cell Biol</source>
<volume>26</volume>
<fpage>9256</fpage>
<lpage>9267</lpage>
<pub-id pub-id-type="pmid">17030624</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Metcalf1">
        <label>63</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Metcalf</surname><given-names>CE</given-names></name><name><surname>Wassarman</surname><given-names>DA</given-names></name></person-group>
<year>2006</year>
<article-title>DNA binding properties of TAF1 isoforms with two AT-hooks.</article-title>
<source>J Biol Chem</source>
<volume>281</volume>
<fpage>30015</fpage>
<lpage>30023</lpage>
<pub-id pub-id-type="pmid">16893881</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Robles1">
        <label>64</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robles</surname><given-names>LM</given-names></name><name><surname>Wampole</surname><given-names>JS</given-names></name><name><surname>Christians</surname><given-names>MJ</given-names></name><name><surname>Larsen</surname><given-names>PB</given-names></name></person-group>
<year>2007</year>
<article-title>Arabidopsis enhanced ethylene response 4 encodes an EIN3-interacting TFIID transcription factor required for proper ethylene response, including ERF1 induction.</article-title>
<source>J Exp Bot</source>
</element-citation>
      </ref>
      <ref id="pone.0002721-Martins1">
        <label>65</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martins</surname><given-names>CP</given-names></name><name><surname>Brown-Swigart</surname><given-names>L</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group>
<year>2006</year>
<article-title>Modeling the therapeutic efficacy of p53 restoration in tumors.</article-title>
<source>Cell</source>
<volume>127</volume>
<fpage>1323</fpage>
<lpage>1334</lpage>
<pub-id pub-id-type="pmid">17182091</pub-id></element-citation>
      </ref>
      <ref id="pone.0002721-Dressman1">
        <label>66</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dressman</surname><given-names>HK</given-names></name><name><surname>Hans</surname><given-names>C</given-names></name><name><surname>Bild</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>JA</given-names></name><name><surname>Rosen</surname><given-names>E</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.</article-title>
<source>Clin Cancer Res</source>
<volume>12</volume>
<fpage>819</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="pmid">16467094</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>